Thirteen million Americans take prescription sleep medications most days or every day. According to the CDC’s 2024 National Health Interview Survey, 5.2% of U.S. adults use prescription sleep aids daily or near-daily, alongside 5.7% using OTC products and 3.7% using marijuana or CBD. This is not a niche issue. It is a mainstream health system experience — and it sits at the intersection of clinical risk and insurance coverage decisions that I have studied closely.

As a researcher working on Alzheimer’s disease and drug development failure, I have spent years examining why promising compounds fail and how institutional decisions shape health outcomes. That work led me to the literature on sedative-hypnotic medications and cognitive risk — and to a conclusion I found appalling when I encountered it in practice. A 2026 systematic review and meta-analysis covering 721,354 subjects found Z-drugs associated with Alzheimer’s disease at an odds ratio of 1.14, and benzodiazepines at 1.21. A separate 2026 community cohort study found benzodiazepine and Z-drug users had an odds ratio of 1.66 for cognitive impairment, including MCI and dementia, confirmed on face-to-face clinical assessment. Doxepin above 10 mg/day was already flagged as a high-risk anticholinergic in JAMA Internal Medicine in 2015, and a 2026 cell-model study showed dose-dependent neurotoxicity. These are not marginal effects. They are documented risks with quantified magnitudes.

What I found appalling was not the existence of these risks — that is what the literature is for. It was the behavior of a coverage entity, Ambetter, that disputed coverage of a Doxepin prescription and pushed a step therapy switch toward Z-drugs or benzodiazepines. From a research standpoint, this is not a neutral substitution. It is a coverage decision that steers a patient toward drug classes with documented cognitive risks, and it does so in the name of cost management rather than clinical judgment. The evidence base does not support that trade. The decision contradicts it.

KFF Health News has already covered the drug classes in question. They have reported on benzodiazepine and Z-drug use in older adults, citing Columbia University psychiatrist Mark Olfson on how these drugs “may impair balance, coordination, and cognition that can translate into falls and fractures and motor vehicle accidents.” Their own reporting notes that prescribed use rose among those over 75, and that about a third of users take the drug for longer than six months. They have the clinical thread. What remains missing is the coverage thread — the step therapy mandates that push patients toward these drugs in the first place.

That coverage thread belongs in KFF’s prior authorization reporting channel. Step therapy is a form of prior authorization, and their “Share Your Story” page actively solicits prior authorization accounts. The gap is not that the topic is trivial. The gap is that it has been pitched as a clinical grievance rather than a consumer-system failure. Insurers are not just denying drugs. They are steering millions of patients toward medications with known cognitive risks — and the patients bearing those risks are often the ones least able to absorb them.

I am sharing this because I have the records, the publications, and the research background to document it — and because I suspect I am not the only one who has watched a coverage decision contradict the evidence it claims to serve. If you have been forced through step therapy toward a drug you and your prescriber did not choose, that is not a personal failing. It is a system design problem. And it is one that reporters are already equipped to cover, if the story reaches them framed the right way.

𝐊𝐅𝐅 𝐍𝐞𝐰𝐬 𝐟𝐮𝐦𝐛𝐥𝐞𝐬 𝐭𝐡𝐞 𝐛𝐚𝐥𝐥.